• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » UPDATE: Ray Elliott on Boston Scientific’s Q2 sales, earnings slide

UPDATE: Ray Elliott on Boston Scientific’s Q2 sales, earnings slide

July 21, 2010 By MassDevice staff

BSX logo

Boston Scientific Corp. (NYSE:BSX) regained its footing during the second quarter, despite a damaging hiatus on sales of its implantable cardiac defibrillators that contributed to a 7 percent top-line decline.

The Natick, Mass.-based medical device maker posted net income of $98 million, or 6 cents per diluted share, on sales of $1.93 billion during the three months ended June 30. That compares with net income of $158 million, or 10 cents per diluted share, on sales of $2.07 billion during the same period last year.

Despite the 38 percent bottom-line slide, president and CEO Ray Elliott said he was "proud" of the way the company rebounded from a month-long suspension of ICD sales that began March 15, when Boston Scientific discovered that it had missed a pair of filings with the Food & Drug Administration.

"In CRM, we finished the quarter well ahead of where we expected to be, thanks to exceptional execution by the sales team and everyone else involved in our recovery," Elliott said in prepared remarks.

Sales for BSX’s cardiac rhythm management division in the U.S. were $322 million, down 20.5 percent compared with $405 million during Q2 2009. Leerink Swann analyst Rick Wise, in a research note to clients, called the results "less bad than feared" and said Boston Scientific beat Leerink’s sales estimate by about $55 million. Worldwide sales for the CRM division were $527 million during the quarter, down 13.5 percent compared with $609 million during the same period last year.

"Overall," Wise wrote, "we view BSX’s results as basically encouraging."

That despite slumping numbers for another key BSX business: coronary stents. U.S. sales of drug-eluting and bare-metal stents were down 12.6 percent to $221 million during the quarter, from $253 million a year ago. Worldwide stent sales dropped to $422 million, a 12.8 percent decline from $484 million during Q2 2009.

In a conference call with analysts, Elliott cited pricing pressure, stiff competition and delays in product launches as contributors to the company’s performance.

“We’re not happy with our sales performance,” he said. “We must do a better job executing to our sales plans. … We have been struggling for quite a while.”

Elliott said he expects the company to “get to market types of growth” in the second half of the year, especially as BSX’s new products — 30 alone this year from the recently combined cardiac rhythm management/cardiovascular group — hit the market.

“We’ve got the products,” CFO Jeff Capello added. “We’ve got the sales people. We’ll have to see how that plays out in the back half of the year.”

Boston Scientific slipped in a positive note just before the end of the quarter when it refinanced a looming, $1.75 billion debt payment due next April. The June 23 move involved an upgrade to its $1.75 billion credit line with a pair of new credit arrangements worth $3 billion, which the company used to pay off the $1.75 billion it owes next year.

BSX also raised its full-year guidance to sales of between $7.6 billion and $7.9 billion and adjusted earnings of 54 cents to 62 cents per share. That’s up from its previous earnings estimate of 50 cents to 60 cents per share.

For the third quarter, Boston Scientific predicted net sales of between $1.85 billion and $1.93 billion and adjusted earnings of between 10 cents and 13 cents per share.

BSX shares were down 0.32 percent to $6.25 in early-morning trading.

Material from MedCity News was used in this report.

Filed Under: Business/Financial News, MassDevice Earnings Roundup, News Well Tagged With: Boston Scientific

In case you missed it

  • FDA says 44 more deaths have been reported in Philips ventilator recall
  • Paragonix reaches milestone of 2,000 organs preserved, transported for transplantation
  • Axonics expands IP portfolio with new patents
  • BD, Accelerate Diagnostics partner on rapid antibiotic testing
  • FDA clears VySpine’s VyPlate anterior cervical plate system
  • Technical Brief – “Understanding the Extensive OEM Benefits of Total Linear Motion Solutions.”
  • Exactech launches total hip arthroplasty system
  • Lensar announces first patients treated with Ally adaptive cataract treatment
  • HeartBeam submits heart attack diagnostic platform for FDA 510(k) clearance
  • GE Healthcare leads AliveCor Series F funding for ECG tech
  • New FDA ruling may lower costs for over-the-counter hearing aids
  • Data supports Sight Sciences’ Omni surgical system for glaucoma
  • Integra founder Richard Caruso has died
  • Moximed raises $40M for implantable shock absorber for knee osteoarthritis
  • Philips names Roy Jakobs as CEO amid ventilator, CPAP recalls
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Dyad Medical wins FDA clearance for cardiac imaging platform Echo:Prio

RSS From Medical Design & Outsourcing

  • What Laura Mauri learned from a ‘firestorm’ in her first months at Medtronic
    Dr. Laura Mauri faced a monumental moment with former Medtronic CEO Omar Ishrak shortly after she joined the company as VP of global clinical research and analytics. It was late 2018, and Mauri — who’s now an SVP and the chief scientific, medical and regulatory officer at Medtronic (NYSE: MDT) — was in a meeting… […]
  • Senators seek post-market FDA study of pulse oximeters and skin color
    Democratic U.S. senators are prodding the FDA to launch a post-market study of pulse oximeters due to unreliable performance for patients with dark skin. Pulse oximeters estimate blood oxygen levels (SpO2) and pulse rates in patients using infrared light — usually on a fingertip — at home or in clinical settings. Blood oxygenation is one… […]
  • TE Connectivity opens global medical device prototyping center in Ireland
    TE Connectivity (NYSE:TEL) today announced it opened its global Propelus Prototype Center for medical devices in Galway, Ireland. The $5 million rapid prototyping center was built into its existing manufacturing site in Galway and directly connects TE engineers with customers to reduce development time and increase speed to market for lifesaving and life-improving medical devices. Propelus… […]
  • Contract manufacturer Minnetronix Medical launches its first in-house product, MindsEye
    Minnetronix Medical has launched MindsEye, making it the first medical device that the contract developer and manufacturer has conceived and commercialized. St. Paul-based Minnetronix Medical’s MindsEye is the first expandable brain access port on the market. The FDA cleared the device under the 510(k) pathway in August 2020. The minimally invasive device gives neurosurgeons deep… […]
  • What’s next for Jennifer Fried after leaving Explorer Surgical?
    Explorer Surgical co-founder Jennifer Fried has resigned from the company after selling it to Global Healthcare Exchange in October. Fried announced her departure last week on LinkedIn, saying she’s preparing for her next professional chapter. “It’s bittersweet — I’m so proud of everything our team has built and accomplished,” Fried wrote. “The time has flown… […]
  • The 24 best medical device innovations of 2022
    The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products designed to improve the human condition.… […]
  • FDA issues new COVID-19 testing guidance to avoid false negatives
    COVID-19 testing should be repeated following a negative result on any antigen test, the FDA said in a move that could increase demand for diagnostics manufacturers. The latest guidance from the federal health agency is for negative COVID-19 antigen test results regardless of the presence or absence of symptoms. The federal agency said recent studies… […]
  • Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production
    Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility. The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing. “Confluent has experienced consistent and strong growth in… […]
  • FDA’s breakthrough medical device designations tally nears 700
    Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted almost 700 designations over the past seven years under a voluntary program for expedited regulatory review of medical devices and combination products that facilitate more effective treatment or diagnosis of serious diseases. According to recent metrics published by FDA, the agency has issued a total of… […]
  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy